Immunovo B.V.

Gastrine

Description

Patients with pancreatic cancer usually present with advanced disease and have a poor prognosis. ImmuNovo’s approach is to develop a therapeutic vaccine, based on gastrin, that will lead to the induction of anti-gastrin antibodies.

Patients with pancreatic cancer usually present with advanced disease and have a poor prognosis. The median survival depends on the stage of the disease at presentation, but is usually on the order of 4 to 6 months for metastatic disease. Current treatments for inoperable pancreatic cancer make little impact on the median survival. Several novel strategies are under active investigation. These include immunotherapy which involves the stimulation of a patient’s immune system to achieve anti-tumor activity. Attempts can be made to enhance the immune response to tumor antigens, non-specifically stimulate the immune system, or induce the formation of antibodies with anti-tumor activity. The role of gastrin as a tumor growth factor in gastro-intestinal cancer and specifically in pancreatic adenocarcinoma is well established. ImmuNovo’s approach is to develop a therapeutic vaccine, based on gastrin, that will lead to the induction of anti-gastrin antibodies. Therefore, we have decided to start immunization strategies with peptides that are based on the bioactive Gastrin 1-17 and 1-34.

Details

  • Date April 3, 2015
  • Tags Product
Back to Top